All In Biotech

Drug Trial Radar · NCT06333964

A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of AST-001 Followed by an Open-Label Extension Treatment Period in Children With Autism Spectrum Disorder

Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

169

Actual

Start

Aug 29, 2023

Primary completion

Dec 5, 2024

Study completion Dec 5, 2024

Sponsor

Lead sponsor
Astrogen, Inc.Industry
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD. 2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD. 3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period

Conditions

  • Autism Spectrum Disorder

Interventions

  • AST-001Drug

    AST-001, PO bid for 24weeks (dosage according to weight range)

  • Placebo of AST-001Drug

    Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. K-VABS-II (Korean-Vineland Adaptive Behavior Scale-II)Time frame: Baseline, 12week, 24week

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • Koera University Guro Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • Soon Chun Hyang University Hospital Cheonan

    Cheonan, Chungcheongnam-do, South Korea

  • Hallym University Medical Center

    Anyang-si, Gyeonggi-do, South Korea

  • Samsung Changwon Medical Center

    Changwon, Gyeongsangnam-do, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, South Korea

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.